| 摘要 |
The disclosure provides a method for determining if a subject afflicted with cancer is a candidate for Programmed Death Ligand-1 (PD-Ll) targeted immunotherapy, which method comprises (a) providing a liquid biopsy sample obtained from the subject afflicted with cancer; (b) detecting CTCs in the liquid biopsy sample; (c) calculating what proportion of CTCs in the liquid biopsy express PD-Ll; and (c) identifying the subject as a candidate for PD-Ll targeted immunotherapy based on an assessment that the proportion of the CTCs in the liquid biopsy that express PD-Ll exceeds a pre-determined threshold level. |
